These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20410767)

  • 41. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Spannuth WA; Thaker PH; Sood AK
    Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    Burling MJ; Gamet K; Eva L; Tan AL
    Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Ghezelayagh TS; Pennington KP; Norquist BM; Khasnavis N; Radke MR; Kilgore MR; Garcia RL; Lee M; Katz R; Leslie KK; Risques RA; Swisher EM
    Gynecol Oncol; 2021 Mar; 160(3):786-792. PubMed ID: 33375991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
    Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
    Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [BRCA1 and BRCA2 mutations in families studied in the program of genetic counselling in cancer of the Valencian community (Spain)].
    Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Barragán González E; Oltra Soler S; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Cuevas Cuerda D; Salas Trejo D;
    Med Clin (Barc); 2008 Feb; 130(4):121-6. PubMed ID: 18279628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
    Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
    Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Boitano TKL; Barrington DA; Batra S; McGwin G; Turner TB; Farmer MB; Brown AM; Straughn MJ; Leath CA
    Gynecol Oncol; 2019 Aug; 154(2):379-382. PubMed ID: 31196574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
    Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
    Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
    Golmard L; Delnatte C; Laugé A; Moncoutier V; Lefol C; Abidallah K; Tenreiro H; Copigny F; Giraudeau M; Guy C; Barbaroux C; Amorim G; Briaux A; Guibert V; Tarabeux J; Caputo S; Collet A; Gesta P; Ingster O; Stern MH; Rouleau E; de Pauw A; Gauthier-Villars M; Buecher B; Bézieau S; Stoppa-Lyonnet D; Houdayer C
    Oncogene; 2016 Mar; 35(10):1324-7. PubMed ID: 26028024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
    Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
    J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
    Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.